Vertex Pharmaceuticals' Kalydeco, or ivacaftor, topped Genetic Engineering & Biotechnology News' list of best-selling drugs that were approved and commercialized last year based on 2012 sales figures. Kalydeco generated sales of $171.6 million. Medivation and Astellas Pharma's Xtandi, or enzalutamide, came in second with $71.5 million, followed by Pfizer's Inlyta, or axitinib, with $70.1 million. Rounding out the top five were Onyx Pharmaceuticals' Kyprolis, or carfilzomib, and Roche Holding's Perjeta, or pertuzumab. The list includes the dates of approval in the U.S. and/or Europe.
Published in Brief: